Genomic mutations, adverse cytogenetic aberrations, and treatment characteristics of 50 relapsed/refractory MM patients. All patients are identified by individual numbers. Refractory status to IMiDs or PIs at any time before sampling is shown as well as PD and refractory (IMiD, PI, other drug classes) status immediately before sampling. Information on the adverse cytogenetic aberrations gain 1q21 (>2 copies), deletion (17p), and translocations t(4;14) and t(14;16) are depicted. Genes mutated in at least 1 patient are displayed. Genes (from top to bottom) and patients (from left to right) are sorted according to gene mutation frequencies. Treatment characteristics and cytogenetic aberrations are color-coded: red, yes; green, no; gray, unknown/not available. Refractory drugs immediately prior to sampling are also color-coded: purple, IMiD refractory; blue, PI refractory; orange, other drug classes (including cytotoxic agents and antibodies); green, not refractory to treatment immediately prior to sampling.